KdT Ventures’ Post

ELEGEN today announces its first partnership with GSK- $35M to start with more to come. Cell-free, clonal, scaled (1G+)DNA manufactured in 7 days or less is the only way we enable personalized genetic medicine- and I can confidently say only ELEGEN can do this. The recent Moderna Lancet publication on their Phase II personalized Melanoma Vaccine (20 unique antigens per patient)last week said it best: "Logistical complexity is intrinsic to personalized neoepitope selection and manufacture...future development must continue to optimize methods to facilitate timely manufacturing." Sure we all know that timely manufacturing is key, but get this. The paper also mentioned in the discussion that the " delayed separation <of the two trial arms> might be partly attributable to the manufacturing time of mRNA-4157". ELEGEN will save time, money, and lives. Best kind of investment. Only frustrating part is seeing so many inferior technologies get gobs of funding based on hype. Customers see the power here, and GSK will be the first of many. #personalizedmedicine #dna #mrna #mrnavaccines